The efficacy and safety of venetoclax combined with reduced dose HAD regimen in the treatment of newly diagnosed acute myeloid leukemia(AML)was investigated.From May 2022 to January 2023,a total of 25 patients with newly diagnosed AML were treated with venetoclax combined with reduced-dose HAD regimen as induction therapy.Accoding to the 2017 ELN recommendations,13(52.0％)in favoable,3(12.0％)in intemediate,and 9(36.0％)in adverse.The ORR(CR rate+PR rate)was 88.0％,and the CR rate was 84.0％.By May 30,2023,with a median follow-up of 9 months,1 year overall survival,event-free survival,and relapse-free survival were 100％,94.7％,and 94.7％,respectively.All patients received 1-5 cycles of consolidation therapy and two median cycles.Treatment with venetoclax and reduced dose of HAD regimen in the treatment of patients with newly diagnosed AML was high effective and safe.
NETL
NSTL
万方数据
